Nykode Therapeutics announces completion of patient enrollment in its Phase 2 trial of VB10.16 in combination with atezolizumab for the treatment of advanced cervical cancer
Nykode Therapeutics has reached the enrollment target of 50 patients in its VB C-02 trial…
Pitches and Keynote Speakers Are Confirmed for Blue Magic Netherlands on November 17
The 34th Hong Kong International Optical Fair opens today
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment
Payment Cards Group (A3A PayTech) Joins HKMA’s Agentic Finance Expert Group
Three Million Fewer Members, JPY97.5 Billion More Revenue: APEC Lands in Shenzhen and China’s Gym Industry Is Being Recomposed